← Back to Screener
NervGen Pharma Corp. Common stock (NGEN)
Price$4.16
Favorite Metrics
Price vs S&P 500 (26W)36.69%
Price vs S&P 500 (4W)-5.18%
Market Capitalization$338.84M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)7.21x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.17
Price vs S&P 500 (YTD)-30.33%
EPS (TTM)$-0.26
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-0.26
EPS (Annual)$-0.26
ROI (Annual)-150.77%
Cash / Share (Quarterly)$0.11
ROA (Last FY)-86.79%
EBITD / Share (TTM)$-0.26
ROE (5Y Avg)-127.95%
Cash Flow / Share (Annual)$-0.22
P/B Ratio334.31x
P/B Ratio (Quarterly)146.47x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-3.86x
ROA (TTM)-158.08%
EPS Incl Extra (Annual)$-0.26
Current Ratio (Annual)2.27x
Quick Ratio (Quarterly)0.77x
3-Month Avg Trading Volume0.11M
52-Week Price Return89.34%
Tangible BV / Share (Quarterly)$0.01
52-Week High$8.49
EPS Excl Extra (Annual)$-0.26
26-Week Price Return39.57%
Quick Ratio (Annual)2.25x
13-Week Price Return-12.12%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)0.79x
Enterprise Value$330.574
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.28
3-Month Return Std Dev61.49%
Net Income / Employee (TTM)$-2
ROE (Last FY)-153.94%
Net Interest Coverage (Annual)-2.99x
EPS Basic Excl Extra (Annual)$-0.26
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$-0.26
ROI (TTM)-392.44%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.16
Price vs S&P 500 (52W)70.47%
Year-to-Date Return-32.94%
5-Day Price Return-6.36%
EPS Normalized (Annual)$-0.26
ROA (5Y Avg)-102.74%
Month-to-Date Return-3.74%
Cash Flow / Share (TTM)$-0.24
EBITD / Share (Annual)$-0.27
LT Debt / Equity (Annual)1.46x
ROI (5Y Avg)-127.32%
LT Debt / Equity (Quarterly)2.53x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)216.86x
P/B Ratio (Annual)6.97x
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)-9.42%
Beta1.45x
ROE (TTM)-399.62%
52-Week Low$2.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NGENNervGen Pharma Corp. Common stock | — | — | — | — | $4.16 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
NervGen Pharma is a clinical-stage biotech company developing therapies to enable the nervous system to repair itself following injury or disease. The company's initial focus is spinal cord injury, with lead candidates NVG-291 and NVG-300 in its pipeline.